Tiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice

Journal of Nutritional Biochemistry

Volumn 23, Issue 7, 2012, Pages 768-776

  Goto, Tsuyoshi ^a   Teraminami, Aki ^a   Lee, Joo Young ^a   Ohyama, Kana ^a   Funakoshi, Kozue ^a   Kim, Young Il ^a   Hirai, Shizuka ^a   Uemura, Taku ^a   Yu, Rina ^b   Takahashi, Nobuyuki ^a   Kawada, Teruo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b University of Ulsan   (South Korea)

Author keywords

Adiponectin; AMPK; Fatty acid oxidation; Insulin resistance; PPAR ; Tiliroside

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ANTIOBESITY AGENT; FATTY ACID; FLAVONOID GLYCOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MESSENGER RNA; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TILIROSIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FEMALE; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID LIVER LEVEL; LIVER; LUNG GAS EXCHANGE; METABOLIC REGULATION; MOUSE; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; FATTY ACIDS; FEMALE; FLAVONOIDS; INSULIN; INTRA-ABDOMINAL FAT; LIPID METABOLISM; LIVER; METABOLIC DISEASES; MICE; MICE, OBESE; MUSCLE, SKELETAL; OBESITY; PLANT EXTRACTS; PPAR ALPHA; RECEPTORS, ADIPONECTIN; SIGNAL TRANSDUCTION; TRIGLYCERIDES; UP-REGULATION; WEIGHT GAIN;

FRAGARIA X ANANASSA; MUS; RUBUS GLAUCUS;

EID: 84859208777     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.04.001     Document Type: Article

References (64)

1. Cornier M.A., Dabelea D., Hernandez T.L., Lindstrom R.C., Steig A.J., Stob N.R., et al. The metabolic syndrome. Endocr Rev 2008, 29:777-822.
2. Yach D., Stuckler D., Brownell K.D. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 2006, 12:62-66.
3. Unger R.H., Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 2001, 15:312-321.
4. van Herpen N.A., Schrauwen-Hinderling V.B. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol Behav 2008, 94:231-241.
5. Harborne J.B., Williams C.A. Advances in flavonoid research since 1992. Phytochemistry 2000, 55:481-504.
6. Beecher G.R. Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr 2003, 133:3248S-3254S.
7. Ross J.A., Kasum C.M. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002, 22:19-34.
8. Timberlake C.F., Henry B.S. Plant pigments as natural food colours. Endeavour 1986, 10:31-36.
9. Arts I.C., Hollman P.C. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005, 81:317S-325S.
10. García-Lafuente A., Guillamón E., Villares A., Rostagno M.A., Martínez J.A. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm Res 2009, 58:537-552.
11. Peluso M.R. Flavonoids attenuate cardiovascular disease, inhibit phosphodiesterase, and modulate lipid homeostasis in adipose tissue and liver. Exp Biol Med (Maywood) 2006, 231:1287-1299.
12. Kwon O., Eck P., Chen S., Corpe C.P., Lee J.H., Kruhlak M., et al. Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J 2007, 21:366-377.
13. Murase T., Nagasawa A., Suzuki J., Hase T., Tokimitsu I. Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver. Int J Obes Relat Metab Disord 2002, 26:1459-1464.
14. Tsuda T. Regulation of adipocyte function by anthocyanins; possibility of preventing the metabolic syndrome. J Agric Food Chem 2008, 56:642-646.
15. Matsuda H., Ninomiya K., Shimoda H., Yoshikawa M. Hepatoprotective principles from the flowers of Tilia argentea (linden): structure requirements of tiliroside and mechanisms of action. Bioorg Med Chem 2002, 10:707-712.
16. Ninomiya K., Matsuda H., Kubo M., Morikawa T., Nishida N., Yoshikawa M. Potent anti-obese principle from Rosa canina: structural requirements and mode of action of trans-tiliroside. Bioorg Med Chem Lett 2007, 17:3059-3064.
17. Tsukamoto S., Tomise K., Aburatani M., Onuki H., Hirorta H., Ishiharajima E., et al. Isolation of cytochrome P450 inhibitors from strawberry fruit, Fragaria ananassa. J Nat Prod 2004, 67:1839-1841.
18. Sala A., Recio M.C., Schinella G.R., Máñez S., Giner R.M., Cerdá-Nicolás M., et al. Assessment of the anti-inflammatory activity and free radical scavenger activity of tiliroside. Eur J Pharmacol 2003, 461:53-61.
19. Tomczyk M., Drozdowska D., Bielawska A., Bielawski K., Gudej J. Human DNA topoisomerase inhibitors from Potentilla argentea and their cytotoxic effect against MCF-7. Pharmazie 2008, 63:389-393.
20. Rao Y.K., Geethangili M., Fang S.H., Tzeng Y.M. Antioxidant and cytotoxic activities of naturally occurring phenolic and related compounds: a comparative study. Food Chem Toxicol 2007, 45:1770-1776.
21. Matsuo T., Shino A. Induction of diabetic alterations by goldthioglucose-obesity in KK,ICR and C57BL mice. Diabetologia 1972, 8:391-397.
22. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
23. Muniyappa R., Lee S., Chen H., Quon M.J. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2009, 294:E15-E26.
24. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
25. Waki H., Yamauchi T., Kamon J., Ito Y., Uchida S., Kita S., et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003, 278:40352-40363.
26. Kuroyanagi K., Kang M.S., Goto T., Hirai S., Ohyama K., Kusudo T., et al. Citrus auraptene acts as an agonist for PPARs and enhances adiponectin production and MCP-1 reduction in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2008, 366:219-225.
27. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
28. Takahashi N., Kawada T., Yamamoto T., Goto T., Taimatsu A., Aoki N., et al. Overexpression and ribozyme-mediated targeting of transcriptional coactivators CREB-binding protein and p300 revealed their indispensable roles in adipocyte differentiation through the regulation of peroxisome proliferator-activated receptor gamma. J Biol Chem 2002, 277:16906-16912.
29. Takahashi N., Kawada T., Goto T., Yamamoto T., Taimatsu A., Matsui N., et al. Dual action of isoprenols from herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HepG2 hepatocytes. FEBS Lett 2002, 514:315-322.
30. Goto T., Takahashi N., Kato S., Egawa K., Ebisu S., Moriyama T., et al. Phytol directly activates peroxisome proliferator-activated receptor alpha (PPARalpha) and regulates gene expression involved in lipid metabolism in PPARalpha-expressing HepG2 hepatocytes. Biochem Biophys Res Commun 2005, 337:440-445.
31. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006, 580:2917-2921.
32. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-451.
33. Minokoshi Y., Kim Y.B., Peroni O.D., Fryer L.G., Müller C., Carling D., et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343.
34. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
35. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
36. Tsuda T., Ueno Y., Aoki H., Koda T., Horio F., Takahashi N., et al. Anthocyanin enhances adipocytokine secretion and adipocyte-specific gene expression in isolated rat adipocytes. Biochem Biophys Res Commun 2004, 316:149-157.
37. Shin D.W., Kim S.N., Lee S.M., Lee W., Song M.J., Park S.M., et al. (-)-Catechin promotes adipocyte differentiation in human bone marrow mesenchymal stem cells through PPAR gamma transactivation. Biochem Pharmacol 2009, 77:125-133.
38. Vasseur F., Helbecque N., Dina C., Lobbens S., Delannoy V., Gaget S., et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 2002, 11:2607-2614.
39. Pajvani U.B., Hawkins M., Combs T.P., Rajala M.W., Doebber T., Berger J.P., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004, 279:12152-12162.
40. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
41. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13:332-339.
42. Braissant O., Foufelle F., Scotto C., Dauça M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137:354-366.
43. Muoio D.M., MacLean P.S., Lang D.B., Li S., Houmard J.A., Way J.M., et al. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J Biol Chem 2002, 277:26089-26097.
44. Debard C., Laville M., Berbe V., Loizon E., Guillet C., Morio-Liondore B., et al. Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of type 2 diabetic patients. Diabetologia 2004, 47:917-925.
45. Staiger H., Kaltenbach S., Staiger K., Stefan N., Fritsche A., Guirguis A., et al. Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes 2004, 53:2195-2201.
46. Huang H., Iida K.T., Sone H., Yokoo T., Yamada N., Ajisaka R. The effect of exercise training on adiponectin receptor expression in KKAy obese/diabetic mice. J Endocrinol 2006, 189:643-653.
47. Kelley D.E., Goodpaster B., Wing R.R., Simoneau J.A. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 1999, 277:E1130-E1141.
48. Kim J.Y., Hickner R.C., Cortright R.L., Dohm G.L., Houmard J.A. Lipid oxidation is reduced in obese human skeletal muscle. Am J Physiol Endocrinol Metab 2000, 279:E1039-E1044.
49. Bruce C.R., Anderson M.J., Carey A.L., Newman D.G., Bonen A., Kriketos A.D., et al. Muscle oxidative capacity is a better predictor of insulin sensitivity than lipid status. J Clin Endocrinol Metab 2003, 88:5444-5451.
50. Lindén D., William-Olsson L., Rhedin M., Asztély A.K., Clapham J.C., Schreyer S. Overexpression of mitochondrial GPAT in rat hepatocytes leads to decreased fatty acid oxidation and increased glycerolipid biosynthesis. J Lipid Res 2004, 45:1279-1288.
51. Lindén D., William-Olsson L., Ahnmark A., Ekroos K., Hallberg C., Sjögren H.P., et al. Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation. FASEB J 2006, 20:434-443.
52. Stefanovic-Racic M., Perdomo G., Mantell B.S., Sipula I.J., Brown N.F., O'Doherty R.M. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. Am J Physiol Endocrinol Metab 2008, 294:E969-E977.
53. Akkaoui M., Cohen I., Esnous C., Lenoir V., Sournac M., Girard J., et al. Modulation of the hepatic malonyl-CoA-carnitine palmitoyltransferase 1A partnership creates a metabolic switch allowing oxidation of de novo fatty acids. Biochem J 2009, 420:429-438.
54. Bruce C.R., Hoy A.J., Turner N., Watt M.J., Allen T.L., Carpenter K., et al. Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance. Diabetes 2009, 58:550-558.
55. Houstis N., Rosen E.D., Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440:944-948.
56. Manach C., Morand C., Demigné C., Texier O., Régérat F., Rémésy C. Bioavailability of rutin and quercetin in rats. FEBS Lett 1997, 409:12-16.
57. Walle T., Otake Y., Walle U.K., Wilson F.A. Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr 2000, 130:2658-2661.
58. Paganga G., Rice-Evans C.A. The identification of flavonoids as glycosides in human plasma. FEBS Lett 1997, 401:78-82.
59. Aziz A.A., Edwards C.A., Lean M.E., Crozier A. Absorption and excretion of conjugated flavonols, including quercetin-4'-O-beta-glucoside and isorhamnetin-4'-O-beta-glucoside by human volunteers after the consumption of onions. Free Radic Res 1998, 29:257-269.
60. Tsuda T., Horio F., Osawa T. Absorption and metabolism of cyanidin 3-O-beta-d-glucoside in rats. FEBS Lett 1999, 449:179-182.
61. Shimoi K., Yoshizumi K., Kido T., Usui Y., Yumoto T. Absorption and urinary excretion of quercetin, rutin, and alphaG-rutin, a water soluble flavonoid, in rats. J Agric Food Chem 2003, 51:2785-2789.
62. Makino T., Shimizu R., Kanemaru M., Suzuki Y., Moriwaki M., Mizukami H. Enzymatically modified isoquercitrin, alpha-oligoglucosyl quercetin 3-O-glucoside, is absorbed more easily than other quercetin glycosides or aglycone after oral administration in rats. Biol Pharm Bull 2009, 32:2034-2040.
63. da Silva W.S., Harney J.W., Kim B.W., Li J., Bianco S.D., Crescenzi A., et al. The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation. Diabetes 2007, 56:767-776.
64. Tsuchida A., Yamauchi T., Takekawa S., Hada Y., Ito Y., Maki T., et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005, 54:3358-3370.